PIM2 and breast carcinoma: To investigate if PIM2 and HK2 conferred paclitaxel resistance in breast cancer cells, we analyzed the effects of PIM2 and HK2 knockdown on the cell proliferation rates of MCF-7/TaxR cells following paclitaxel treatment.